Over 10 years we help companies reach their financial and branding goals. Engitech is a values-driven technology agency dedicated.



411 University St, Seattle, USA


+1 -800-456-478-23

Unleash the power of AI
transform patient data into expert-level care

Clinical users
Patients onboarded
Expert level treatment recommendations facilitated
logged events by patient users in the patient App
Watch Introduction

The Market Opportunity

Diabetes impacts hundreds of millions of people globally. Rapid technological advances have led to increased medication options and an explosion of diabetes device adoption worldwide. Between now and 2030, experts project an 8.2% compound annual growth rate (CAGR) for the diabetes device market. 

Unfortunately, the vast majority of people living with diabetes still do not have access to expert level care. There is a massive shortage of experts both in the U.S. and globally. In the U.S., there is only one endocrinologist for every 6,000 people diagnosed with diabetes.  As a result, only a small percentage of patients have access to expert level care. The remaining majority either are dependent on care providers who are not equipped to deliver expert-level diabetes care, or have no access at all.


DreaMed is solving this problem by unleashing the power of AI to transform patient data into expert level treatment recommendations. DreaMed has proven AI can be used to emulate a clinical expert, and that software can be used to transform any care provider into an expert. As a result, massive amounts of patient data can now be processed and interpreted at global scale. Indeed, with this technology we can now help to ensure all patients have access to expert-level treatment recommendations when and where they need it.

DreaMed technology is cleared by the FDA, so care providers and patients can trust the treatment recommendations generated are at an expert level. The technology can be used to transform any care provider into an expert, including primary care physicians, pharmacists, RNs, PAs, diabetes educators, patients themselves and their care givers.

“endo.digital is an algorithm that indeed “thinks” like a diabetes expert.”

Professor Stuart A. Weinzimer
Yale School of Medicine


DreaMed’s first product launch is endo.digital, a cloud-based SAAS platform that gives care provider organizations an end-to-end diabetes care pathway that can be deployed across all care settings where patients with diabetes are treated, both remotely and in person. It is the only decision support software cleared by the FDA to support both Type 1 and Type 2 diabetes.

endo.digital Capabilities Include:
Diabetes device and health data uploader

Single platform to acquire patient data from the vast majority of diabetes devices on the market

FDA cleared AI enhanced decision support

Turn every provider into an expert while unifying standard of care across providers and care settings

Automated payer billing documentation

Increase revenue capture for payer CPT codes

Patient Mobile App

Increase patient engagement and adherence in between visits

EMR workflow integration

Seamless access via the patient record, and automated data push into the EMR workflow


Deployments have resulted in quantifiable results that align to top enterprise priorities. 

Clinical Outcomes

FDA-cleared AI clinical decision support proven to be on par with expert physicians.
(p-value < 0.01)

Nimri R et al, Nature Medicine, Vol 26(9), 2020
Nimri R et al, Diabetes Technol Ther, Vol 24(8), 2022
Nimri R et al, J Diabetes Sci Technol, Vol 16(2), 2022
Nimri R et al, Diabetes Obes Metab. 2018, Vol 20(10), 2018

Freeing Up Staff Capacity

8.9 minutes time savings per patient visit to acquire, interpret, and document diabetes device data.

Dec 2022 – Feb 2023 pre/post time study of endo.digital deployment presented by Dr. Benaviv-Meskin, Feb 2023 at the ATTD in Berlin.

Increasing revenue

39% increase in CGM code 95251 billed to payers.
(p-value < 0.01)

2022-2023 study of customer 95251 reimbursement. N= 3465 baseline patient visits; 3527 measurement period patient visits.
*Baseline imputed based on 15% 95251 captures versus 20% actual capture post deployment

Patient Engagement

51% of patients continue using the patient app after 90 days, compared to other industry benchmarks ranging from 10% to 24%.

2022 customer data at pediatric endocrinology practice.
N=183 patients


DreaMed is partnering with some of the leading institutions in the world to pioneer the way AI technology can revolutionize patient care.

DreaMed Diabetes Deploys Diabetes Data Management and Clinical Decision Support Device Into Patients’ Electronic Medical Records at Yale New Haven Health
Business Wire Article
University of Colorado School of Medicine Will Work with DreaMed Diabetes to Deploy Its Advisor System
Business Wire Article
DreaMed partners with Billings Clinic to bring personalized expert level diabetes care to Montana's health network
PR Newswire Article
DreaMed announces it will be serving as a subcontractor on a $5M+ grant from The Leona M. and Harry B. Helmsley Charitable Trust to the Jaeb Center for Health Research Foundation. 
Hit Consultant Article
Dexcom and DreaMed Diabetes Announce Collaboration to Integrate Dexcom CGM Data into DreaMed Advisor
Business Wire Article
T1D Exchange and DreaMed Diabetes Formalize Partnership to Optimize Insulin Treatment Plans in Clinics
AP News Article


Lisa Stump
Lisa Stump
SVP, Chief Information and Digital Transformation Officer, Yale New Haven Health System
“My organization deals with many technology vendors. Care for patients with diabetes adds to this challenge due to all the disparate diabetes devices required for these patients. This new technology will not only improve clinical operations but reduce the need for multiple integrations and installations by the IT team.”
Lisa Ranes
Lisa Ranes
RD LN CDNES Manager of Diabetes Endocrinology and Metabolism Center
“endo.digital is the only platform in the market positioned to deliver a true one-stop shop solution. The platform supports my staff’s entire workflow, from data acquisition, interpretation to the documentation we need for payer reimbursement. This is especially important in today’s very tight budget environment, where we need to be able to show hard dollar value in order to justify budget for new software. Not only is endo.digital saving my staff time and helping them deliver great care, but also demonstrated a significant increase in capturing revenue for the work my staff is doing.”
Dr. Kate Garvey
Dr. Kate Garvey
Clinical Chief of Diabetes, Boston Children’s
“There is no alternative on the market that offers the scope of FDA-cleared decision support offered by endo.digital. Our clinical team members trust the recommendations generated by the algorithm. This not only saves us time, but also gives lower licensure staff the confidence they can trust the output without the extra burden of doing additional analysis or getting approval from a higher licensure clinician”
Dena Mccusker
Dena Mccusker
Mother of Cameron who is living with T1D
“endo.digital has been a game-changer for my daughter’s A1C! The algorithm has empowered us to analyze components available in the basal and bolus settings that seem to have been overlooked for years."